What is Adjuvant Therapy Market?
Adjuvant therapy is a term used to encompass all of the extra treatments given in addition to surgery to help reduce the chance of breast cancer recurrence. “Adjuvant” therapy is used after the primary treatment, which is usually surgery, to lessen the chance of breast cancer coming back. Even though surgery was successful at removing all visible cancer, microscopic cancer cells that are undetectable with current methods may remain. Adjuvant therapy for breast cancer is designed to treat “micrometastatic” disease, or breast cancer cells that have escaped the breast and regional lymph nodes, but have not yet established an identifiable metastasis.
The market study is being classified by Type (Radiation Therapy, Chemotherapy, Immunotherapy, Hormone Therapy and Targeted Therapy), by Application (Hospital, Clinics and Ambulatory Surgical Centers) and major geographies with country level break-up.
Merck (United States), Bayer (Germany), PFIZER (United States), Johnson & Johnson (United States), AstraZenca (United Kingdom), TAKEDA (Japan), SANOFI (France), Mylan (United States), AbbVie (United States) and Novartis (Switzerland) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Eli Lilly (United States), Novo Nordisk (Denmark) and Bristol-Myers Squibb (United States).
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Adjuvant Therapy market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Adjuvant Therapy market by Type, Application and Region.
On the basis of geography, the market of Adjuvant Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Rising Prevalence Of Micrometastatic Disease, Or Breast Cancer
- Growing Awareness Regarding Health Among Individuals
- Strong R&D Initiatives From Key Companies Are All Driving Adjuvant Therapy
- Stringent Regulations, And Long Product Approval Process
- Increase In Awareness About The New Approach To Treat Cancer Leads To Increase In Demand For Adjuvant Therapy
- Government Favorable Incentives For Cancer Treatment
- High Cost Associated With Adjuvant Therapy
- Challenges To Develop Adjuvant Therapy Products
Market Leaders and some development strategies
On 11 March 2022, Pfizer Inc. announced the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.
On 15 October, 2021, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test.
Key Target AudienceAdjuvant Therapy, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others
Frequently Asked Questions (FAQ):
1. Which factors would majorly drive the Adjuvant Therapy Market?
"Rising Prevalence Of Micrometastatic Disease, Or Breast Cancer
" is seen as one of major growth factors of Adjuvant Therapy Market in years to come.
2. Can we have customized study for Adjuvant Therapy Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
3. Which region will lead the Global Adjuvant Therapy Market?
United States will lead Adjuvant Therapy Market in coming years.